Dose wisely! How lipid-lowering undertreatment can lead to overtreatment

Affiliations

¹ Research Unit of Lipids and Atherosclerosis, University Rovira i Virgili, C. Sant Llorenç 21, 43201, Reus, Spain. Electronic address: luis.masana@urv.cat.
² Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands.

Editorial

Luis Masana et al. Atherosclerosis. 2016 Dec.

. 2016 Dec:255:126-127.

doi: 10.1016/j.atherosclerosis.2016.10.014. Epub 2016 Oct 8.

¹ Research Unit of Lipids and Atherosclerosis, University Rovira i Virgili, C. Sant Llorenç 21, 43201, Reus, Spain. Electronic address: luis.masana@urv.cat.
² Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands.

No abstract available

Keywords: LDL cholesterol; LDL targets; Lipid lowering therapy; PCSK9 inhibitors; Treatment adherence; Undertreatment.

Comment on

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Gitt AK, et al. Atherosclerosis. 2016 Dec;255:200-209. doi: 10.1016/j.atherosclerosis.2016.09.004. Epub 2016 Sep 9. Atherosclerosis. 2016. PMID: 27667299